Dimensional Fund Advisors’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-224,658
| Closed | -$2.94M | – | 3220 |
|
|
2025
Q4 | $2.94M | Buy |
224,658
+9,242
| +4% | +$110K | ﹤0.01% | 2651 |
|
|
2025
Q3 | $1.57M | Sell |
215,416
-5,493
| -2% | -$37.2K | ﹤0.01% | 2823 |
|
|
2025
Q2 | $1.18M | Buy |
220,909
+36,830
| +20% | +$179K | ﹤0.01% | 2861 |
|
|
2025
Q1 | $983K | Sell |
184,079
-93,993
| -34% | -$658K | ﹤0.01% | 2887 |
|
|
2024
Q4 | $2.49M | Sell |
278,072
-2,241
| -0.8% | -$23.8K | ﹤0.01% | 2732 |
|
|
2024
Q3 | $3.09M | Buy |
280,313
+134,155
| +92% | +$1.49M | ﹤0.01% | 2673 |
|
|
2024
Q2 | $1.33M | Buy |
146,158
+133,379
| +1,044% | +$1.3M | ﹤0.01% | 2862 |
|
|
2024
Q1 | $180K | Buy |
+12,779
| New | +$159K | ﹤0.01% | 3199 |
|
|
2023
Q1 | – | Sell |
-17,521
| Closed | -$261 | – | 3463 |
|
|
2022
Q4 | $261 | Hold |
17,521
| – | – | ﹤0.01% | 3178 |
|
|
2022
Q3 | $158K | Buy |
+17,521
| New | +$117K | ﹤0.01% | 3274 |
|
|
2021
Q3 | – | Sell |
-10,241
| Closed | -$130K | – | 3503 |
|
|
2021
Q2 | $130K | Buy |
10,241
+1,941
| +23% | +$25.2K | ﹤0.01% | 3386 |
|
|
2021
Q1 | $144K | Sell |
8,300
-1,505
| -15% | -$27.2K | ﹤0.01% | 3318 |
|
|
2020
Q4 | $126K | Sell |
9,805
-33,732
| -77% | -$601K | ﹤0.01% | 3263 |
|
|
2020
Q3 | $1.62M | Buy |
43,537
+1,009
| +2% | +$40K | ﹤0.01% | 2804 |
|
|
2020
Q2 | $1.64M | Buy |
42,528
+1,532
| +4% | +$54.6K | ﹤0.01% | 2818 |
|
|
2020
Q1 | $1.02M | Buy |
40,996
+1,600
| +4% | +$49.6K | ﹤0.01% | 2886 |
|
|
2019
Q4 | $1.4M | Buy |
39,396
+1,852
| +5% | +$58.4K | ﹤0.01% | 2943 |
|
|
2019
Q3 | $1.22M | Buy |
37,544
+1,102
| +3% | +$43.6K | ﹤0.01% | 2972 |
|
|
2019
Q2 | $1.76M | Buy |
36,442
+11,740
| +48% | +$533K | ﹤0.01% | 2929 |
|
|
2019
Q1 | $1.17M | Buy |
+24,702
| New | +$838K | ﹤0.01% | 3000 |
|
|
2018
Q3 | – | Sell |
-2,550
| Closed | -$147K | – | 3426 |
|
|
2018
Q2 | $147K | Sell |
2,550
-289
| -10% | -$26.6K | ﹤0.01% | 3276 |
|
|
2018
Q1 | $308K | Hold |
2,839
| – | – | ﹤0.01% | 3171 |
|
|
2017
Q4 | $254K | Buy |
2,839
+2,562
| +925% | +$301K | ﹤0.01% | 3185 |
|
|
2017
Q3 | $35K | Buy |
+277
| New | +$23.1K | ﹤0.01% | 3314 |
|
Dimensional Fund Advisors's ATXS Position: Q1 2026 in Review
Dimensional Fund Advisors sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 224,658 shares — an estimated $2.94M sold.
Dimensional Fund Advisors first reported a position in ATXS in Q3 2017 and held it in 24 quarters. The position peaked at $3.09M in Q3 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Dimensional Fund Advisors reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Dimensional Fund Advisors sold 224,658 Astria Therapeutics shares in Q1 2026, an estimated $2.94M.
- Dimensional Fund Advisors first reported a position in Astria Therapeutics in Q3 2017 and held it in 24 quarters.
- Dimensional Fund Advisors's Astria Therapeutics position peaked at $3.09M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.